Evidence map›Paper›PMID 39139673›Full record

ArticleFrontiers in public health2024

Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis.

Chika Yamamoto, Yurie Kobashi, Takeshi Kawamura, Yoshitaka Nishikawa, Hiroaki Saito, Fumiya Oguro, Tianchen Zhao, Morihito Takita, Toyoaki Sawano, Akihiko Ozaki and 7 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chika YamamotoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Yurie KobashiDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Takeshi KawamuraProteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan.
Yoshitaka NishikawaDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Fukushima, Japan.
Hiroaki SaitoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Fumiya OguroDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Fukushima, Japan.
Tianchen ZhaoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Morihito TakitaDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Toyoaki SawanoDepartment of Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan.
Akihiko OzakiDepartment of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan.
Toshiki AbeDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Naomi ItoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Yudai KanekoLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Aya NakayamaProteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Tatsuhiko KodamaLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Masaharu TsubokuraDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vaccination has been implemented as a useful measure to combat the COVID-19 pandemic. However, there is a tendency for individuals to avoid vaccination due to the possibility of adverse events, making it important to investigate the relationship between COVID-19 vaccines and their adverse events. This study explored longitudinal adverse event patterns and factors that influence adverse events following the second to fourth doses of the COVID-19 vaccine through a latent class analysis. Methods: Participants were recruited from the Fukushima Prefecture and included individuals who had completed four doses of the COVID-19 mRNA vaccine. This study utilized data from questionnaire surveys and blood collection conducted between September 2021 and November 2022. In the questionnaire, factors such as sex, age, medical history, medication, type of vaccine administered, and adverse events following vaccination were recorded. Additionally, in the blood data, serological tests [IgG(S)] and cellular immune responses (T-spot) were measured. Descriptive statistics, latent class analysis, multivariable logistic regression, and multiple regression analyses were performed to identify the longitudinal adverse event patterns and influencing factors. By analyzing adverse events over time, we identified two distinct groups: those less prone to experiencing adverse events (Group 1) and those more susceptible (Group 2) to latent class analysis. Results: A total of 1,175 participants were included after excluding those without any adverse events. The median age of the participants in Group 1 was 70 years, and in Group 2 it was 51 years. The proportion of female participants was 298 in Group 1 and 353 in Group 2. Patients in Group 2 were significantly younger ( Discussion: Our findings suggest that factors other than age, particularly sex and a history of allergies, significantly influence the likelihood of experiencing adverse events. Groups categorized by latent class analysis for longitudinal adverse events are expected to be valuable for optimizing vaccination strategies and formulating public health measures.

Indexed as

COVID-19COVID-19 VaccinesAgedFemaleHumansJapanLatent Class AnalysisLongitudinal StudiesMaleMiddle AgedSurveys and QuestionnairesVaccinationCOVID-19 Vaccinesadverse eventsCOVID-19Fukushima cohortlatent class analysisvaccination

Identifiers

PMID39139673
PMCPMC11320210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.